Spelling suggestions: "subject:"founctional 2studies"" "subject:"founctional 3studies""
1 |
The pharmacology of an antisense oligonucleotide to the α2A/D-adrenoceptorRobinson, Emma S. J. January 1999 (has links)
No description available.
|
2 |
Post-GWAS functional characterisation of colorectal cancer risk lociOoi, Li Yin January 2016 (has links)
Large bowel cancer, or colorectal cancer (CRC) is the third most common cause of cancer worldwide and the fourth biggest cause of cancer mortality. Twin studies have shown that the heritable contribution is ~35%, with ~5% of cases due to rare, high-penetrance mutations. In the last decade, the use of genome-wide association studies on large, well-characterised case-control cohorts of CRC has facilitated the identification of over 25 common genetic variants that carry with them an increased predisposition to colorectal cancer, invoking the common-disease common variant paradigm. As almost all of these variants lie within non-coding regions, the underlying causal mechanism is to-date poorly understood for the majority of these loci, and it is thought that they mediate risk by influencing gene expression levels. To test this hypothesis, an agnostic approach that utilises expression quantitative trait loci (eQTL) analysis was first carried on 115 normal colorectal mucosa samples and 59 peripheral blood mononuclear cells (PBMC). As these heritable variation on gene expression are likely to be subtle, there is a strong emphasis on the technical methodology to minimise experimentally-induced non-biological variations, including the extraction of high-quality RNA from primary tissue, the selection and validation of reference genes for normalisation of gene expression quantification, as well as internal validation of the samples and data processing. Thereafter, the association between the 25 CRC risk variants and the expression of their cis-genes were examined systematically, demonstrating that ten of these variants are also tissue-specific eQTLs. This intermediate phenotype strongly suggests that they confer risk, at least in part, by modifying regulatory mechanisms. One of the best eQTL associations (Xp22.2) is investigated in further detail to reveal a novel indel polymorphism (Indel24) at the distal promoter region of target gene SHROOM2 that influenced both transcript abundance and CRC risk more than the original tagging SNP. Functional verification with gene reporter assays indicated that Indel24 displays differential allelic control over transcriptional activity. Further in silico analysis and mutations to the reporter gene constructs provided evidence that Indel24 modulates transcription by modifying the spacing between CCAAT motifs and the consequent binding affinity of NF-Y transcription factor. siRNA depletion of NF-Y was associated with a reduction in transcriptional activity of the Indel24 gene construct as well as endogenous SHROOM2, which is strongly supportive of the interaction between Indel24 and NF-Y in the transcriptional activation of SHROOM2. Preliminary evidence is suggestive of SHROOM2 being expressed at the top of the intestinal epithelial crypt and playing a role in cell cycle regulation. Hypothesis-driven approaches can also be of utility in demonstrating functionality of CRC risk variants, complementing the hypothesis-free approach of eQTL analysis. Guided by a recently discovered gene-environment interaction between the 16q22.1 risk variant and circulating vitamin D levels, the influence of the rs9929218 SNP on CDH1 gene expression was examined, in relation to the expression of putative regulatory genes derived from in silico analysis and studies of other target genes. Although there was no direct association between rs9929218 and CDH1 expression, there were multiple two-way interactions that were together suggestive of rs9929218 influencing the VDR/FOXO4 regulation of CDH1. This provides functional support for the mechanism underlying the epidemiological observation of the gene-environment interaction between 16q22.1 and vitamin D, and demonstrates a candidate-based approach in deciphering the link between genetic locus and CRC susceptibility. In summary, the research presented in this thesis has validated the experimental rationale of utilising expression studies of normal colorectal mucosa to hone in on the molecular mechanisms and susceptibility genes underlying the association between common genetic variation and CRC risk.
|
3 |
Functional Studies and X-Ray Structure Analysis of Human Interleukin-5 Receptor Alpha and Human Interleukin-5 ComplexPatiño Gonzalez, Edwin January 2007 (has links) (PDF)
Interleukin-5 (IL-5) is a member of the hematopoietic class I cytokines and is specifically involved in eosinophil activation. IL-5 plays an important role in disease conditions such as allergic asthma and other hypereosinophilias, which are characterized by highly increased levels of eosinophils in peripheral blood and tissues. The IL-5 receptor is a heterodimer consisting of a binding alpha subunit (IL- 5Rα) and a common beta subunit (IL-5Rβ). This IL-5Rβ is shared with the IL-3 and GM-CSF receptors. The IL-5Rα is required for ligand-specific binding, whereas the association of the IL-5Rβ subunit triggers intracellular signal transduction. Previous studies have described the crystallographic structure of human IL-5 (hIL-5), as well as that of the common IL-5Rβ chain (IL-5Rβc) However, no experimental structural data are yet available for the interaction of the high-affinity IL-5 receptor IL-5Rα with its ligand IL-5. Therefore, this thesis had the principle objective to gain new insights into the basis of this important agonist-receptor interaction. In particular, data on the recombinant expression, purification and preparation of the binary complex of hIL-5 bound to the receptor ectodomain of hIL-5Rα are shown, as well as the subsequent crystal structure analysis of the binary ligand-receptor (hIL-5Rα/hIL-5) complex. Both proteins were expressed in an Escherichia coli expression system, purified to homogeneity, and crystallized. However, since the initial analysis of these crystals did not show any X-ray diffraction, each step of the preparation and crystallization procedure had to be stepwise optimized. Several improvements proved to be crucial for obtaining crystals suitable for structure analysis. A free cysteine residue in the N-terminal domain of the hIL-5Rα ectodomain protein was mutated to alanine to remove protein heterogeneity. In addition, hIL-5 affinity chromatography of the receptor protein proved to be absolutely crucial for crystal quality. Additive screening using the initial crystallization condition finally yielded crystals of the binary complex, which diffracted to 2.5Å resolution and were suitable for structure analysis. The preliminary structure data demonstrate a new receptor architecture for the IL-5Rα ligand-binding domain, which has no similarities to other cytokine class I receptor structures known so far. The complex structure demonstrates that the ligand-binding region of human IL-5Rα is dispersed over all three extracellular domains, and adopts a binding topology in which the cytokine recognition motif (CRM) needs the first Fn-III domain of the human IL-5Rα to bind the ligand. In a second project, a prokaryotic expression system for murine IL-5 (mIL-5) was established to allow the production of mIL-5 and mIL-5 antagonist that should facilitate functional studies in mice. Since the expression of mIL-5 in E. coli had never been successful so far, a fusion protein system was generated expressing high yields of mIL-5. Chemical cleavage with cyanogen bromide (CNBr) was used to release mIL-5 monomers, which were subsequently purified and refolded. This technique yielded an active murine IL-5 dimer as confirmed by TF-1 cell proliferation assays. The protein was crystallized and the structure of mIL-5 could be determined at 2.5Å resolution. The molecular structure revealed a symmetrical left-handed four helices bundle dimer similar to human IL-5. Analysis of the structure-/function relationship allowed us to design specific mIL-5 antagonist molecules, which are still under examination. Taken together, these findings provide further insights in the IL-5 and IL-5R interaction which may help to further understand and depict this and other cytokine-receptor interactions of similar architecture, e.g. the IL-13 ligand-receptor system. Ultimately, this may represent another piece of puzzle in the attempts to rationally design and engineer novel IL-5-related pharmacological therapeutics. / Interleukin-5 (IL-5) ist ein Mitglied der Gruppe der hematopoetischen Zytokine der Klasse I und spielt eine Schlüsselrolle bei der Aktivierung von eosinophilen Granulozyten. IL-5 hat damit ein wichtige pathophysiologische Funktion bei der Entstehung von Krankheiten wie allergischem Asthma und anderen Hypereosinophilien, die alle durch eine stark erhöhte Zahl von Eosinophilen in peripherem Blut und Geweben charakerisiert sind. Der IL-5 Rezeptor ist ein Heterodimer, der aus einer alpha-Untereinheit (IL-5Rα) und einer mit den IL-3 und GM-CSF Rezeptoren gemeinsamen beta-Untereinheit (IL-5Rβ) besteht. Der IL-5Rα ist für die spezifische Liganden-Bindung notwendig, während der mit der IL-5Rβ Untereinheit assozierte Komplex die intrazelluläre Signaltransduktion einleitet. In früheren Studien konnte bereits die Kristallstruktur des menschlichen IL-5 (hIL-5) und der gemeinsamen IL-5Rβ-Kette (IL-5Rβc) aufgeklärt werden. Allerdings liegen bisher noch keine experimentellen Strukturdaten für die Interaktionen des hochaffinen IL-5 Rezeptor IL-5Rα mit seinem Ligand IL-5 vor. Deshalb war es die Hauptzielsetzung dieser Arbeit, neue Einblicke in die molekulare Basis der Interaktion von IL-5 Rezeptor und Agonisten zu gewinnen. Im Einzelnen beschreibe ich in dieser Arbeit die rekombinante Expression, Aufreinigung und Herstellung des binären Komplexes von der hIL-5 Bindung an die extrazellulären Domäne des Rezeptors hIL-5Rα sowie die anschließende kristallographische Strukturanalyse dieses binären Ligand-Rezeptor-Komplexes (hIL-Rα/hIL-5). Beide Proteine wurden in einem Escherichia coli-Expressionssystem rekombinant hergestellt, bis zur Homogenität gereinigt und anschließend kristallisiert. Die Analysen dieser ersten Kristalle zeigten nicht die gewünschte Beugung der Röntgenstrahlung, weshalb in allen anschließenden Schritten eine schrittweise Optimierung der Produktions- und Kristallisationsbedingungen durchgeführt wurde. Als Ergebnis dieser Optimierungsstrategie konnten schließlich Kristalle erhalten werden, die für eine Strukturanalyse geeignet waren. Ein ungepaartes Cystein in der N-terminalen Domäne des extrazellulären hIL-5Rα-Protein wurde durch Alanin ersetzt, um so die Protein-Heterogenität durch Cystein-Oxidationsprodukte zu verringern. Die affinitätschromatographische Aufreinigung des Rezeptorproteins war ebenfalls entscheidend, um eine hohe Kristallqualität zu erreichen. Die Verwendung verschiedener Additivsubstanzen zusätzlich zu der initialen Kristallisationsbedingungen führte letztlich zur Bildung für die Strukturanalyse geeigneter Einzelkristallen des binären Komplexes (hIL-5Rα/hIL-5). Ihre Messung ergab Beugungsdaten mit einer maximalen Auflösung von 2.5Å. Eine erste Strukturanalyse zeigt klar, dass die Liganden-bindende Domäne des IL-5Rα Rezeptors eine bisher unbekannte, neuartige Rezeptor-Architektur aufweist, die keinerlei Ähnlichkeit zu bisher bekannten Zytokinrezeptor-strukturen der Klasse I hat. Die Struktur des Komplexes zeigt zudem, dass das Liganden-bindende Epitop von IL-5Rα über alle drei extrazelluläre Domänen verteilt ist und eine Topologie aufweist, in der zusätzlich zu dem Zytokin-Erkennungsmotiv (CRM) die erste Fn-III Domäne von hIL-5Rα benötigt wird, um den Liganden hochaffin binden zu können. In einem zweiten Projekt wurde ein prokaryotisches Expressionssystem für murines Interleukin-5 (mIL-5) entwickelt, welches die Produktion von mIL-5 und eines mIL-5 Antagonisten für funktionelle Studien in einem Mausmodell ermöglichen sollte. Da eine rekombinante Produktion von mIL-5 in E.coli bisher nicht erfolgreich war, wurde ein Fusionsproteinsystem entwickelt, welches die Produktion großer Mengen von mIL-5 Protein erlaubt. Es wurde eine chemische Spaltung mit Cyanbromid (CNBr) durchgeführt, um das Monomer aus dem Fusionsprotein freizusetzen. Das so erhaltene mIL-5 Monomer wurde gereinigt und renaturiert. Nach Rückfaltung zeigt das dimere Protein in TF-1 Zellen eine mit den Literaturwerten vergleichbare biologische Aktivität. Das so erhaltene mIL-5 Protein wurde kristallisiert und mittels Röntgenbeugung analysiert. Auf diese Weisen konnten Beugungsdaten von mIL-5 Kristallen mit einer maximalen Auflösung von 2.5Å erhalten werden. Die Struktur weist ähnlich wie das humane IL-5 ein symmetrisches Vier-Helix Bündel auf. Die Struktur-/Funktionsanalyse ermöglichte daraufhin, definierte mIL-5-Antagonisten zu entwickeln, die sich derzeit noch in der Untersuchung befinden. Zusammengefasst tragen die hier präsentierten Ergebnisse dazu bei, die molekularen Grundlagen der spezifischen IL-5 und IL-5R Bindung sowie Interaktionen ähnlichen Liganden-Rezeptor-Typen zu verstehen. Letztendlich besteht die Hoffnung, dass diese und ähnliche Arbeiten ein weiteres wichtiges Puzzlestück darstellen bei dem Versuch, neue und innovative pharmakologische Therapieansätze zu entwickeln, die bei dem für die Pathophysiologie von Asthma wichtigen Schlüsselmolekül IL-5 angreifen.
|
4 |
Structural and Functional Studies of Non-Homologous End-Joining Regulator 1 (NEJ1)Sulek, Margaret 08 1900 (has links)
<p> Repair of double-strand breaks is critical for the preservation of genomic integrity and cellular viability. A predominant pathway implicated in the repair of such lesions is the evolutionarily conserved non-homologous end-joining (NHEJ) pathway. Among the major constituents of this pathway in Saccharomyces cerevisiae is Nej1, for which a clear biochemical function has not been determined. The results presented in this work demonstrate that Nej1 exhibits a DNA binding activity comparable to Lif1, with an apparent dissociation constant of 1.8 μM. Characterization of the DNA binding activity revealed that although short ~20 bp substrates can suffice, binding is enhanced with longer substrates (>300). This DNA binding activity supports the hypothesis that Nej1 plays a direct role in the repair of DNA double-strand breaks. Structure-function studies indicated that the C-terminus of Nej1 is not only required, but is sufficient, for mediating DNA interactions. Structural characterization revealed that Nej1 exists as a dimer, and that residues 1-244 are sufficient for dimer formation. Examining the ability of this truncated Nej1 (aa 1-244) to perform NHEJ, revealed a defect in end-joining as measured by an in vivo plasmid repair assay. Preliminary functional and structural studies on the Nej1-Lif1 complex suggest that the proteins stably co-purify and the complex binds DNA with a higher affinity than each independent component. The significance of these results is discussed with reference to current literature on Nej1 and other end-joining factors (mammalian and yeast), specifically the recently identified putative mammalian
homologue of Nej1, XLF. Collectively, these results demonstrate that although there are several functional similarities, there also appear to be important differences in the structure-function relationships of Nej1 and XLF, and Nej1/XLF and Lif1/Xrcc4.</p> / Thesis / Master of Science (MSc)
|
5 |
Caracterização funcional in vitro de variantes no gene PCSK9 identificadas em pacientes com Hipercolesterolemia Familial / In vitro functional characterization of PCSK9 variants identified in patients with Familial HypercholesterolemiaLos, Bruna 25 June 2019 (has links)
A Hipercolesterolemia Familial (HF) é uma doença genética do metabolismo das lipoproteínas, caracterizada pelo aumento do colesterol plasmático, transportado principalmente pela lipoproteína de baixa densidade (LDL). A HF é causada principalmente por mutações nos genes LDLR, APOB e PCSK9. As mutações conhecidas na PCSK9 podem levar ao aumento ou diminuição da função proteolítica da proteína, as quais são associadas ao aumento ou diminuição da LDL-c plasmática, respectivamente. Com o projeto genoma humano surgiram novos métodos de sequenciamento, o que resultou em um grande número de novas variantes genéticas relacionadas à HF. Entretanto, os mecanismos pelos quais essas variantes influenciam na concentração do colesterol e sua interferência na resposta terapêutica não estão totalmente elucidados. O objetivo do presente trabalho foi avaliar in vitro o efeito de variantes na região codificadora e reguladora do gene PCSK9 identificadas em pacientes HF utilizando sequenciamento de nova geração. Para a caracterização funcional das variantes na região codificadora da PCSK9, primeiramente foi avaliado o impacto dessas variantes na interação PCSK9-LDLR via Docking molecular. Células HEK293FT foram transfectadas com as diferentes construções da PCSK9, e posteriormente, foram utilizadas em ensaios para avaliar a atividade do LDLR e a internalização de LDL por citometria de fluxo. Para as variantes na região reguladora da PCSK9, foi realizado uma predição in silico do possível efeito de variantes na região 3UTR na ligação de miRNAs. A avalição da interação entre os miRNAs preditos, e a região 3UTR da PCSK9, e o possível impacto nessa interação na presença de variantes na região 3UTR, foi realizada em células HEK293FT transfectadas com um plasmídeo contendo a 3UTR da PCSK9 e um gene repórter da Gaussia luciferase, juntamente com um plasmídeo de expressão contendo os miRNAs de interesse. Foi também estudado o efeito dos miRNAs preditos sobre a expressão, RNAm e proteína, da PCSK9 via RT-qPCR e Western blot, em células HepG2. Foram identificadas 9 variantes na região codificadora da PCSK9, e duas, E32K e R469W, foram selecionadas para os ensaios posteriores. Para a R469W foi observada uma possível alteração conformacional a qual poderia aumentar a afinidade da PCSK9 pelo LDLR. Para a E32K, uma possível associação com HF foi observada em uma família brasileira com ascendência japonesa. As variantes E32K e R469W apresentaram uma redução na atividade do LDLR de 5 e 11%, respectivamente em comparação a PCSK9-WT. Entretanto, não foram observadas reduções estaticamente significativas na atividade do LDLR e na internalização da LDL em células transfectadas com ambas as variantes. Dez variantes foram encontradas na região 3UTR da PCSK9, entre elas três foram selecionadas por impactar a ligação de quatro miRNAs. Nossos dados demonstraram uma redução significativa na expressão da PCSK9 em células HepG2 transfectadas com os miR-4721 e miR-564 (p=0,036 e p=0,010, respectivamente). Porém, não foi observada diferenças na expressão da luciferase em células transfectadas com esses miRNAs, não sendo possível validar a interação miRNA-RNAm. As variantes no gene PCSK9 identificadas no nosso estudo podem não explicar individualmente o fenótipo HF, mas podem contribuir para a severidade da doença juntamente com outras variantes em outros genes. / Familial Hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism, characterized by elevated plasma cholesterol levels, mostly carried by low-density lipoprotein (LDL). FH is mainly caused by mutations in three genes, LDLR, APOB, and PCSK9. Gain-of-function mutations in PCSK9 reduce LDL receptor levels, resulting in high levels of LDL cholesterol in the plasma. Loss-of-function mutations lead to higher levels of the LDL receptor, resulting in lower LDL cholesterol levels. The Human Genome Project led to a faster technological development related to sequencing methods, which allowed identifying many novel variants associated with FH. However, the mechanisms by which these variants influence cholesterol levels and their interference in therapeutic response are not fully understood. The aim of the present study was to perform an in vitro characterization of the effect of PCSK9 variants identified in FH patients using Next-Generation Sequencing. For the functional characterization of variants in the coding region of PCSK9, the impact of these variants on PCSK9-LDLR interaction was evaluated by molecular docking. HEK293FT cells were transiently transfected with different PCSK9 constructs, and the amount of cell surface LDLR and LDL internalization were determined by flow cytometry. For the variants in PCSK9 3UTR region, an in silico prediction of PCSK9 3UTR variants in miRNA seed regions and target sites was performed. To determine whether the predicted miRNAs directly interact with PCSK9 3UTR region, HEK293FT cells were co-transfected with a vector containing a PCSK9 3\'UTR region and a Gaussia luciferase reporter gene, together with an expression plasmid containing the miRNAs of interest. The effect of the predicted miRNAs on the expression of PCSK9 was evaluated using RT-qPCR and Western blot in HepG2 cells transiently transfected with miRNA mimics. Nine missense variants were identified in PCSK9 gene. E32K e R469W were chosen for further analysis. For R469W, a possible conformational change was observed that could increase the affinity of PCSK9 for LDLR, when compared to the wild-type. For E32K, a possible association with FH in a Brazilian family with Japanese ancestry was observed. E32K and R469W had a 5% and 11% decreased level of cell surface LDLR, respectively, as compared with WT-PCSK9. However, no significant reduction in the number of cell surface LDLR and LDL internalization was observed in transfected cells for both variants. Ten variants were found in PCSK9 3\'UTR region, of which three were selected for affecting the binding of four miRNAs. Our data demonstrated a significant downregulation of PCSK9 in cells transfected with miR-4721 and miR-564 miRNA mimics, compared to cells transfected with a scramble control (p=0,036 and p=0,010, respectively). However, no differences in luciferase expression were observed in cells transfected with these miRNAs, therefore, it was not possible to experimentally validate miRNA-mRNA interaction. PCSK9 variants found in our study may not fully explain FH phenotype but may contribute to the severity of the disease together with other variants in other genes.
|
6 |
Identificação de mutações no gene do receptor da lipoproteína de baixa densidade (LDLR) em pacientes com hipercolesterolemia familiar / Identification of mutation in the low density lipoprotein receptor gene (LDLR) in familial hypercholesterolemia patientsVasconcelos, Karina Alves da Silva 15 January 2015 (has links)
Hipercolesterolemia familiar (HF) é uma doença autossômica dominante, caracterizada por elevados níveis plasmáticos da lipoproteína de baixa densidade (LDL), desenvolvimento de xantoma tendíneo e arco corneal, além do aumento do risco de doença coronariana e acidente vascular cerebral prematuros. Frequentemente subdiagnosticada, estima-se que apenas 10% dos 400.000 indivíduos com HF no Brasil têm conhecimento da própria doença; afetando, desta forma, a qualidade e a expetativa de vida dos pacientes. Mutações no gene do receptor da LDL (LDLR) são consideradas as alterações genéticas mais frequentes para o desenvolvimento da hipercolesterolemia familiar, pois comprometem a capacidade de remoção das partículas de LDL circulantes, promovendo seu aumento em níveis plasmáticos. Já foram descritas mais de 1600 mutações diferentes no gene LDLR associadas ao fenótipo da HF; entretanto, ainda é difícil determinar em muitas delas o efeito deletério na atividade do receptor. O objetivo desse estudo foi identificar e caracterizar funcionalmente mutações no gene LDLR não descritas na literatura para determinar sua patogenicidade na hipercolesterolemia familiar. Foi avaliada a atividade residual de LDLR através da captação de LDL marcado com fluoróforo lipofílico em cultura de linfócitos T dos pacientes portadores das mutações analisadas após estimulação dos linfócitos T por mitógenos específicos. As mutações Cys82Ser, Thr404Ser, Gly529Arg e His285Tyr foram consideradas patogênicas por acarretarem diminuição da atividade residual do receptor de LDL. As mutações Glu 602X e His388ProfsX53 confirmaram sua patogenicidade e podem ser considerados como controle positivo para futuros ensaios funcionais. Estudos que esclareçam os mecanismos moleculares da HF e da relação genótipo/fenótipo abrem perspectivas para o desenvolvimento de terapias mais específicas na redução dos níveis de colesterol e, consequentemente, da morbidade e mortalidade associadas às doenças cardiovasculares. / Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by elevated plasma levels of low-density lipoprotein (LDL), and development of corneal arcus tendinous xanthoma, and increased risk of coronary heart disease and premature stroke. Often misdiagnosed, it is estimated that only 10% of the 400.000 patients with FH in Brazil has knowledge of the disease itself, affecting in this way the quality and life expectancy of patients. Mutations in the LDL receptor (LDLR) are considered the most frequent genetic alterations for the development of familial hypercholesterolemia because compromise the ability of removal of circulating LDL particles, promoting its increase in plasma levels. Have been described over 1600 different mutations in the LDLR gene associated with the phenotype of FH, however, it is still difficult to determine in many of the deleterious effects on receptor activity. The aim of this study was to identify mutations in the LDLR gene and functionally characterize mutations not described in the literature to determine its pathogenicity in familial hypercholesterolemia. The residual activity of LDLR was evaluated by raising LDL labeled with lipophilic fluorophore in cultured T lymphocytes of patients with the analyzed mutations after stimulation of T lymphocytes by specific mitogen. The substitution mutations Cys82Ser, Thr404Ser, Gly529Arg e His285Tyr were considered pathogenic because it causes decrease of the residual activity of the LDL receptor in T lymphocytes. The His388ProfsX53 and Glu602X mutations confirmed their pathogenicity and can be considered as positive control for future functional assays. Studies to clarify the molecular mechanisms of HF and genotype/ phenotype open perspectives for the development of more specific therapies for reducing cholesterol levels, and therefore the morbidity and mortality associated with cardiovascular diseases.
|
7 |
Strategies for Identification of Susceptibility Genes in Complex Autoimmune DiseasesProkunina, Ludmila January 2004 (has links)
<p>Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are complex autoimmune diseases affecting 0.05-2% of the population worldwide. </p><p>Genetic studies detected linkage with SLE in the 2q37 region, and intensive family-based and case-control association studies in several populations identified that allele A of the SNP PD-1.3 located in the immunoreceptor PDCD1 (PD-1) gene, increases risk of the disease by 2.6-fold in Caucasians (p<0.00001) and by 3.5-fold in Mexicans (p=0.0009). </p><p>The same allele was found to be a risk factor for lupus nephritis, a severe clinical manifestation of SLE. In Swedish and European-American females with SLE, patients with the allele A had nephritis 1.8 times (p=0.01) more often than patients with allele G .</p><p>Moreover, the allele A was also found 1.8 times (p=0.005) more often in RA patients, negative for the known risk-factors, rheumatoid factor and the shared epitope, than in other groups of patients and controls. </p><p>Functional studies demonstrated that the mechanism behind the SNP PD-1.3 is related to the disruption of the binding site for RUNX transcription factors in the regulatory region. Expression of the PD-1 and RUNX genes was altered in the activated T cells of SLE patients compared to controls.</p><p>The Tumor Necrosis Factor Receptor 2 (TNFR 2) gene was studied as a second candidate gene for both SLE and RA. The results of our studies in SLE and RA patients and controls from Sweden and Mexico do not support the association of the polymorphism TNFR 2 M196R with these diseases. Other polymorphisms in this gene and other genes in this region should therefore be studied.</p>
|
8 |
Strategies for Identification of Susceptibility Genes in Complex Autoimmune DiseasesProkunina, Ludmila January 2004 (has links)
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are complex autoimmune diseases affecting 0.05-2% of the population worldwide. Genetic studies detected linkage with SLE in the 2q37 region, and intensive family-based and case-control association studies in several populations identified that allele A of the SNP PD-1.3 located in the immunoreceptor PDCD1 (PD-1) gene, increases risk of the disease by 2.6-fold in Caucasians (p<0.00001) and by 3.5-fold in Mexicans (p=0.0009). The same allele was found to be a risk factor for lupus nephritis, a severe clinical manifestation of SLE. In Swedish and European-American females with SLE, patients with the allele A had nephritis 1.8 times (p=0.01) more often than patients with allele G . Moreover, the allele A was also found 1.8 times (p=0.005) more often in RA patients, negative for the known risk-factors, rheumatoid factor and the shared epitope, than in other groups of patients and controls. Functional studies demonstrated that the mechanism behind the SNP PD-1.3 is related to the disruption of the binding site for RUNX transcription factors in the regulatory region. Expression of the PD-1 and RUNX genes was altered in the activated T cells of SLE patients compared to controls. The Tumor Necrosis Factor Receptor 2 (TNFR 2) gene was studied as a second candidate gene for both SLE and RA. The results of our studies in SLE and RA patients and controls from Sweden and Mexico do not support the association of the polymorphism TNFR 2 M196R with these diseases. Other polymorphisms in this gene and other genes in this region should therefore be studied.
|
9 |
Etude fonctionnelle de l'Ubinucléine, partenaire cellulaire du facteur de transcription EB1 du virus d'Epstein-Barr et inhibition du cycle lytique viral / 'Ubinuclein functional study, cellular partner of Epstein-barr virus transcription factor EB1 and viral lytic cycle inhibition'Conti, Audrey 14 December 2012 (has links)
Découvert en 1964, le virus d'Epstein-Barr appartient à la famille des gamma-herpèsvirus. Ce virus à ADN présente une forte prévalence (90% de la population adulte est infectée). Ce fut le premier virus identifié comme associé à des cancers (lymphome de Burkitt et d'Hodgkin, carcinome gastrique et de l'oropharynx). Ce virus a pour spécificité de posséder deux cycles distincts : latent et lytique (production de particules virales). Le facteur de transcription viral EB1 (ou Zebra) est un élément clé lors de l'initiation du cycle lytique et semble une cible importante pour l'élaboration de nouveaux traitements. Une première partie de ce travail concerne la caractérisation d'une protéine cellulaire (l'Ubinucléine) qui interagit et inhibe l'activité de EB1. Cette protéine voyage entre noyaux et jonctions serrées. Elle appartient à la famille des « NACos » (nuclear and adhesion complex components). La fonction de l'Ubinucléine n'est pas connue et sa protéomique quand elle est localisée dans les jonctions serrées, a été réalisée. Des études fonctionnelles montrent que l'Ubinucléine interagit avec plusieurs partenaires cellulaires, emprunte la voie d'endocytose dépendante de la clathrine et que sa localisation cellulaire (nucléaire ou dans les jonctions serrées) est affectée par la PKA. Dans une seconde partie, nous nous sommes intéressés à des molécules inhibitrices du facteur de transcription viral EB1. Après criblage à haut débit de composés chimiques (EMBL-Heidelberg), des tests in-vitro ont permis d'en sélectionner un pour des essais in-vivo. Ce composé chimique inhibe l'activité du facteur de transcription EB1 et bloque précocement la mise en place du cycle lytique dans des cellules de lymphome de Burkitt. Il semble donc intéressant d'améliorer l'efficacité et la spécificité de cette molécule. / Discovered in 1964, Epstein-Barr virus belongs to the Gamma-herpesvirus family. This DNA virus shows an important prevalence (90% of the adult population is infected). It was the first virus identified as associated with cancers (Hodgkin and Burkitt lymphomas, Gastric and oropharyngal carcinomas). It presents two distinct cycles: Latency and Lytic cycle (viral particle production). Viral transcription EB1 (or Zebra) is a key element for lytic cycle initiation and seems to be an important target for future treatment development. A first part of this work concerned the characterization of the cellular protein Ubinuclein that inhibits EB1 activity. This protein travels between nucleus and tight junctions. It belongs to the “NACos” (nuclear and adhesion complex components) protein family. Ubinuclein function is not known and its proteomic was performed when it was localized at tight junction. Next, functional studies showed that Ubinuclein interacts with various cellular partners and goes though the clathrin dependent endocytosis pathway. It's localisation (nuclear or at tight junction) changes with PKA activity. In the second part of this work, we focus on viral transcription factor EB1 inhibitors. After high-throughput screening of compounds (EMBL-Heidelberg), in-vitro assays allowed to select one molecule for in-vivo experiments. This compound inhibits the activity of the transcription factor EB1 and stops early lytic cycle establishment in Burkitt lymphoma cells. Further work needs to be done to increase efficacy and specificity of this molecule.
|
10 |
Identificação de mutações no gene do receptor da lipoproteína de baixa densidade (LDLR) em pacientes com hipercolesterolemia familiar / Identification of mutation in the low density lipoprotein receptor gene (LDLR) in familial hypercholesterolemia patientsKarina Alves da Silva Vasconcelos 15 January 2015 (has links)
Hipercolesterolemia familiar (HF) é uma doença autossômica dominante, caracterizada por elevados níveis plasmáticos da lipoproteína de baixa densidade (LDL), desenvolvimento de xantoma tendíneo e arco corneal, além do aumento do risco de doença coronariana e acidente vascular cerebral prematuros. Frequentemente subdiagnosticada, estima-se que apenas 10% dos 400.000 indivíduos com HF no Brasil têm conhecimento da própria doença; afetando, desta forma, a qualidade e a expetativa de vida dos pacientes. Mutações no gene do receptor da LDL (LDLR) são consideradas as alterações genéticas mais frequentes para o desenvolvimento da hipercolesterolemia familiar, pois comprometem a capacidade de remoção das partículas de LDL circulantes, promovendo seu aumento em níveis plasmáticos. Já foram descritas mais de 1600 mutações diferentes no gene LDLR associadas ao fenótipo da HF; entretanto, ainda é difícil determinar em muitas delas o efeito deletério na atividade do receptor. O objetivo desse estudo foi identificar e caracterizar funcionalmente mutações no gene LDLR não descritas na literatura para determinar sua patogenicidade na hipercolesterolemia familiar. Foi avaliada a atividade residual de LDLR através da captação de LDL marcado com fluoróforo lipofílico em cultura de linfócitos T dos pacientes portadores das mutações analisadas após estimulação dos linfócitos T por mitógenos específicos. As mutações Cys82Ser, Thr404Ser, Gly529Arg e His285Tyr foram consideradas patogênicas por acarretarem diminuição da atividade residual do receptor de LDL. As mutações Glu 602X e His388ProfsX53 confirmaram sua patogenicidade e podem ser considerados como controle positivo para futuros ensaios funcionais. Estudos que esclareçam os mecanismos moleculares da HF e da relação genótipo/fenótipo abrem perspectivas para o desenvolvimento de terapias mais específicas na redução dos níveis de colesterol e, consequentemente, da morbidade e mortalidade associadas às doenças cardiovasculares. / Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by elevated plasma levels of low-density lipoprotein (LDL), and development of corneal arcus tendinous xanthoma, and increased risk of coronary heart disease and premature stroke. Often misdiagnosed, it is estimated that only 10% of the 400.000 patients with FH in Brazil has knowledge of the disease itself, affecting in this way the quality and life expectancy of patients. Mutations in the LDL receptor (LDLR) are considered the most frequent genetic alterations for the development of familial hypercholesterolemia because compromise the ability of removal of circulating LDL particles, promoting its increase in plasma levels. Have been described over 1600 different mutations in the LDLR gene associated with the phenotype of FH, however, it is still difficult to determine in many of the deleterious effects on receptor activity. The aim of this study was to identify mutations in the LDLR gene and functionally characterize mutations not described in the literature to determine its pathogenicity in familial hypercholesterolemia. The residual activity of LDLR was evaluated by raising LDL labeled with lipophilic fluorophore in cultured T lymphocytes of patients with the analyzed mutations after stimulation of T lymphocytes by specific mitogen. The substitution mutations Cys82Ser, Thr404Ser, Gly529Arg e His285Tyr were considered pathogenic because it causes decrease of the residual activity of the LDL receptor in T lymphocytes. The His388ProfsX53 and Glu602X mutations confirmed their pathogenicity and can be considered as positive control for future functional assays. Studies to clarify the molecular mechanisms of HF and genotype/ phenotype open perspectives for the development of more specific therapies for reducing cholesterol levels, and therefore the morbidity and mortality associated with cardiovascular diseases.
|
Page generated in 0.0798 seconds